- Home
- FOF vs CCCC Comparison
FOF vs CCCC Comparison
Compare FOF & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOF | CCCC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.8M | 394.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FOF | CCCC |
|---|---|---|
| Price | $12.23 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 64.7K | ★ 2.8M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $11.99 | $1.69 |
| 52 Week High | $15.04 | $5.17 |
Technical Indicators
Market Signals| Indicator | FOF | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 37.18 |
| Support Level | $12.06 | $2.47 |
| Resistance Level | $12.59 | $3.25 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 34.14 | 3.37 |
Price Performance
Historical ComparisonAbout FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. The Fund's investment objective is to achieve total return, consisting of high current income and potential capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.